Provention Bio (NASDAQ:PRVB) issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.11), Fidelity Earnings reports.
NASDAQ PRVB opened at $4.39 on Friday. The stock has a market capitalization of $168.13 million and a P/E ratio of -3.69. Provention Bio has a 12 month low of $1.52 and a 12 month high of $8.00.
A number of analysts have recently issued reports on PRVB shares. Leerink Swann started coverage on Provention Bio in a research report on Friday, February 22nd. They set an “outperform” rating on the stock. Svb Leerink initiated coverage on Provention Bio in a research report on Friday, February 22nd. They set an “outperform” rating and a $6.00 target price for the company. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Provention Bio in a research report on Thursday, April 25th. Finally, Zacks Investment Research upgraded Provention Bio from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research report on Saturday, March 23rd.
Provention Bio Company Profile
Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.
See Also: Consumer behavior in bull markets
Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.